Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.06−0.17 (-2.73%)
Close on Nov 13, 2026Market cap $492.63MP/E –Yield –
Phathom Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Phathom Pharmaceuticals's total debt was $165.54M at Sep 30, 2026. For fiscal 2025 it was $209.09M, up 3.8% from the year before. The highest annual figure on record is $209.09M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.09M | +3.8% |
| FY2024 | Dec 31, 2024 | $201.41M | +46.1% |
| FY2023 | Dec 31, 2023 | $137.84M | +44.7% |
| FY2022 | Dec 31, 2022 | $95.26M | +6.2% |
| FY2021 | Dec 31, 2021 | $89.67M | +90.8% |
| FY2020 | Dec 31, 2020 | $46.99M | +106.3% |
| FY2019 | Dec 31, 2019 | $22.78M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $165.54M | -20.1% |
| Q2 FY2026 | Jun 30, 2026 | $164.59M | -19.8% |
| Q1 FY2026 | Mar 31, 2026 | $163.68M | -19.5% |
| Q4 FY2025 | Dec 31, 2025 | $209.09M | +3.8% |
| Q3 FY2025 | Sep 30, 2025 | $207.09M | +17.8% |
| Q2 FY2025 | Jun 30, 2025 | $205.14M | +17.6% |
| Q1 FY2025 | Mar 31, 2025 | $203.25M | +36.4% |
| Q4 FY2024 | Dec 31, 2024 | $201.41M | +46.1% |
| Q3 FY2024 | Sep 30, 2024 | $175.73M | +77.0% |
| Q2 FY2024 | Jun 30, 2024 | $174.42M | +78.3% |
| Q1 FY2024 | Mar 31, 2024 | $149.02M | +54.2% |
| Q4 FY2023 | Dec 31, 2023 | $137.84M | +44.7% |
| Q3 FY2023 | Sep 30, 2023 | $99.26M | +5.7% |
| Q2 FY2023 | Jun 30, 2023 | $97.81M | +5.8% |
| Q1 FY2023 | Mar 31, 2023 | $96.64M | +6.2% |
| Q4 FY2022 | Dec 31, 2022 | $95.26M | +6.2% |
| Q3 FY2022 | Sep 30, 2022 | $93.88M | +6.3% |
| Q2 FY2022 | Jun 30, 2022 | $92.43M | +93.8% |
| Q1 FY2022 | Mar 31, 2022 | $91.04M | +92.3% |
| Q4 FY2021 | Dec 31, 2021 | $89.67M | +90.8% |
| Q3 FY2021 | Sep 30, 2021 | $88.31M | +89.4% |
| Q2 FY2021 | Jun 30, 2021 | $47.69M | +3.1% |
| Q1 FY2021 | Mar 31, 2021 | $47.35M | +107.9% |
| Q4 FY2020 | Dec 31, 2020 | $46.99M | – |
| Q3 FY2020 | Sep 30, 2020 | $46.62M | – |
| Q2 FY2020 | Jun 30, 2020 | $46.26M | – |
| Q4 FY2019 | Dec 31, 2019 | $22.78M | – |
See a number that looks wrong?